Gastroenterology

  • PENTASA®
    PENTASA®
    (mesalazine)
    (mesalazine)

    Gastroenterology
  • PENTASA® (mesalazine)

    PENTASA® (mesalazine) is licensed for the treatment and long-term management of ulcerative colitis (UC). Pentasa is prescribed to treat mild to moderate active UC as well as being used as maintenance therapy to reduce the risk of recurrent flare-ups.

    Pentasa is available orally as tablets and granules (sachets) and also as topical formulations (suppositories and enemas), to allow administration via the rectum.

    Visit www.pentasasupport.co.uk for more information about ulcerative colitis, Pentasa and the support and services offered for patients taking Pentasa.

    Patients must take Pentasa as directed by their doctor.

    For product specific information, please consult the summaries of product characteristics (SPC) from the link below:

    https://www.medicines.org.uk/emc/search/?q=pentasa&dt=1

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals on telephone: 0844 931 0050 and email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    GO/1003/2015/UK                                                    Date of preparation: August 2015

  • CORTIMENT®
    CORTIMENT®
    (budesonide)
    (budesonide)

    Gastroenterology
  • CORTIMENT® (budesonide)

    CORTIMENT® is indicated for mild-to-moderate active ulcerative colitis where 5-ASA treatment is not sufficient.

    Cortiment is a locally active corticosteroid in an oral tablet formulation, which is licensed to be taken once-daily for up to 8 weeks.

    Patients must take Cortiment as directed by their doctor.

    For product specific information, please consult the summary of product characteristics (SPC) from the link below:

    https://www.medicines.org.uk/emc/medicine/30253

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals on telephone: 0844 931 0050 and email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    GO/1003/2015/UK                                                    Date of preparation: August 2015

  • PICOLAX®
    PICOLAX®
    (sodium picosulphate, magnesium citrate)
    (sodium picosulphate, magnesium citrate)

    Gastroenterology
  • PICOLAX® (sodium picosulphate, magnesium citrate)

    PICOLAX® (sodium picosulphate, magnesium citrate) is indicated in adults and children to clean the bowel prior to X-ray examination or endoscopy, or to clean the bowel prior to surgery when judged clinically necessary.

    Picolax is a powder that contains a laxative, sodium picosulphate, that works by increasing the activity of the bowel. Picolax also contains another laxative, magnesium citrate, that works by holding back fluid in the bowel to provide a wash-out effect.

    It is important patients taking Picolax adhere to the recommended drinking schedule to support effectiveness and avoid dehydration.

    Patients may visit www.picolax.co.uk for information and support while taking Picolax. The website includes; bowel cleansing information, fluid intake sheets, dietary advice and a mode of action animation.

    Patients must take Picolax as directed by their doctor.

    For product specific information, please consult the summary of product characteristics (SPC) from the link below:

    https://www.medicines.org.uk/emc/medicine/670

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals on telephone: 0844 931 0050 and email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    GO/1003/2015/UK                                                    Date of preparation: August 2015

  • VSL#3®
    VSL#3®

    Gastroenterology
  • VSL#3®

    VSL#3® is a probiotic food supplement, containing 8 different strains of bacteria. It is the world’s most concentrated probiotic containing 450 billion live freeze-dried bacteria per sachet.

    While different probiotic products contain different quantities of bacteria, they also contain a different number and type of bacterial strains. Some probiotic dietary supplements contain several strains of beneficial bacteria, while many commonly used probiotic foods contain only a single strain. Importantly, irrespective of the strains used, the bacteria must be able to survive the strong acidic conditions of the stomach; they must be able to adhere to the inner gut wall, and they must, at least temporarily, colonise the intestine.

    The unique VSL#3 formulation contains eight strains of beneficial live lactic acid bacteria,including several strains of the all-important lactobacilli and bifidobacteria:

    • Streptococcus thermophiles
    • Bifidobacterium breve
    • Bifidobacterium longum
    • Bifidobacterium infatis
    • Lactobacillus paracasei
    • Lactobacillus delbrueckii subsp. Bulgaricus
    • Lactobacillus acidophilus
    • Lactobacillus plantarum

    These bacteria have been purposefully selected, carefully cultivated and mixed proportionately to survive gastric acid, bile and pancreatic secretions, as well as colonise the gut. To help ensure they get to where they need to go, the bacteria are freeze dried so they only 'wake up' in the 'warmth' of your gut.

    To find out more about VSL#3, or to order it online, visit www.vsl3.co.uk.

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals on telephone: 0844 931 0050 and email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    GO/1003/2015/UK                                                    Date of preparation: August 2015

  • PreventID® CalScreen®
    PreventID® CalScreen®

    Gastroenterology
  • PreventID® CalScreen®

    PreventID® CalScreen® is a semi-quantitative, rapid point-of-care test for above-normal levels of faecal calprotectin, a marker of inflammatory activity in the bowel.

    The use of this test enables screening of patients with chronic abdominal symptoms and the differentiation between organic (e.g. UC) and functional (e.g. IBS) conditions.

    The test can be completed in primary care and takes 10 minutes to produce a result.

    The National Institute for Health and Care Excellence (NICE) has issued guidance on the use of faecal calprotectin in the differential diagnosis of IBD or IBS.1

    Visit www.calscreen.co.uk for full details, a product demonstration and commissioning support document.

    1. National Institute for Health and Care Excellence. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. Diagnostics Guidance DG11. October 2013.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    GO/1003/2015/UK                                                    Date of preparation: August 2015

  • GLYPRESSIN®
    GLYPRESSIN®
    (terlipressin)
    (terlipressin)

    Gastroenterology
  • GLYPRESSIN® (terlipressin)

    GLYPRESSIN® (terlipressin) is indicated for the treatment of bleeding oesophageal varices. Glypressin is administered to patients by a healthcare professional via an injection.

    For product specific information, please consult the summaries of product characteristics (SPC) from the link below:

    https://www.medicines.org.uk/emc/search/?q=Glypressin&dt=1

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals on telephone: 0844 931 0050 and email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    GO/1003/2015/UK                                                    Date of preparation: August 2015

UK office

Ferring Pharmaceuticals Ltd.
Drayton Hall, Church Road, West Drayton.
UB7 7PS

Telephone : +44(0)8449310050

Contact

Global Locator

Corporate Global Locator

You are now leaving www.Ferring.co.uk , a website of Ferring Pharmaceuticals Ltd UK. Links to all outside websites are provided as a resource to our visitors. Ferring Pharmaceuticals Ltd accepts no responsibility for the content of other websites.